Massey Cancer Center researchers. We reported that VCU uncovered a novel combination of drugs may be effective against acute myeloid leukemia (AML) in preclinical models. The findings were most recently published in the Journal Cancer Research and could point investigators to new and improved treatments for not only AML but also other hematologic malignancies.
Massey physician/investigator Steven Grant, MD has led the effort to find that combining the existing drug venetoclax with an class of agents known as PI3K inhibitors has led to a synergistic number of interactions in AML cells stemming from interruption of the function of BCL-2 proteins and triggering of cell death. Note that BCL-2 proteins help regulate a form of cell suicide known as apoptosis.
Dr. Massey earned his BS from City College of NY in 1969; his MD, Mount Sinai School of Medicine, 1973 and a series of post graduate achievements—see the profile for a review of Dr. Massey’s world class background.